Re: Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication

Journal of the National Cancer Institute

Volumn 106, Issue 8, 2014, Pages

  Rosty, Christophe ^a,c,d   Williamson, Elizabeth J ^e   Clendenning, Mark ^a,b   Walters, Rhiannon J ^a   Walsh, Michael D ^a,f   Win, Aung K ^e   Jenkins, Mark A ^e   Hopper, John L ^e,g   Winship, Ingrid ^b,h   Southey, Melissa C ^b   Giles, Graham G ^e,i   English, Dallas R ^e,i   Buchanan, Daniel D ^a,b,e  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d Envoi Pathology   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f SULLIVAN NICOLAIDES PATHOLOGY   (Australia)

^g Seoul National University   (South Korea)

^h ROYAL MELBOURNE HOSPITAL   (Australia)

ⁱ CANCER EPIDEMIOLOGY CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; MISMATCH REPAIR PROTEIN;

BODY MASS; CANCER DIAGNOSIS; CANCER GRADING; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; COLORECTAL CANCER; COLORECTAL CARCINOMA; FOLLOW UP; GENE MUTATION; HAZARD RATIO; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; IMMUNOHISTOCHEMISTRY; LETTER; MICROSATELLITE INSTABILITY; OVERALL SURVIVAL; PATHOLOGIST; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; TUMOR DIFFERENTIATION; WILD TYPE; COLORECTAL TUMOR; CPG ISLAND; DNA METHYLATION; FEMALE; GENETICS; MALE; MUTATION; NOTE;

COLORECTAL NEOPLASMS; CPG ISLANDS; DNA METHYLATION; FEMALE; HUMANS; MALE; MICROSATELLITE INSTABILITY; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF;

EID: 84907012499     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dju180     Document Type: Letter

References (6)

1. Lochhead P, Kuchiba A, Imamura Y, et al. Microsatellite Instability and BRAF Mutation Testing in Colorectal Cancer Prognostication. J Natl Cancer Inst. 2013;105(15):1151-1156.
2. English DR, Young JP, Simpson JA, et al. Ethnicity and risk for colorectal cancers showing somatic BRAF V600E mutation or CpG island methylator phenotype. Cancer. Epidemiol Biomarkers Prev 2008;17(7):1774-1780.
3. Rosty C, Young JP, Walsh MD, et al. PIK3CA Activating Mutation in Colorectal Carcinoma: Associations with Molecular Features and Survival. PLoS One. 2013;8(6):e65479.
4. Rosty C, Young JP, Walsh MD, et al. Colorectal carcinomas with KRAS mutation are associated with distinctive morphological and molecular features. Mod Pathol. 2013;26(6):825-834.
5. Phipps AI, Buchanan DD, Makar KW, et al. BRAF mutation status and survival after colorectal cancer diagnosis according to patient and tumor characteristics. Cancer Epidemiol Biomarkers Prev. 2012;21(10):1792-1798.
6. Toon CW, Walsh MD, Chou A, et al. BRAFV600E Immunohistochemistry Facilitates Universal Screening of Colorectal Cancers for Lynch Syndrome. Am J Surg Pathol. 2013;37(10):1592-1602.